GO:0010888 negative regulation of lipid storage: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010888 (negative regulation of lipid storage) describes any biological process that decreases the rate, frequency, or extent of lipid storage, a key homeostatic mechanism in adipocytes, hepatocytes, and other cell types.
• Lipid storage is dynamically controlled by the balance between lipogenesis and lipolysis; negative regulation often involves activation of lipases such as ATGL and inhibition of lipid droplet fusion or stabilization.
• Key molecular players include ATGL (PNPLA2), which is subject to N-end rule-mediated proteasomal degradation, thereby promoting lipid storage when degraded.
• Autophagy-related proteins like ATG14 can directly target lipid droplets and act as autophagic receptors, facilitating lipid droplet turnover and reducing lipid storage.
• Dysregulation of negative regulation of lipid storage contributes to metabolic diseases including type 2 diabetes, lipodystrophy, and steatotic liver disease.
• CRISPR-based knockout, knock-in, and overexpression models are essential to dissect causal roles of specific genes in lipid storage regulation and to identify therapeutic targets.
Description
Lipid storage is a fundamental cellular process that involves the accumulation and maintenance of neutral lipids, primarily triglycerides and cholesterol esters, within lipid droplets. This process is critical for energy homeostasis, membrane synthesis, and signaling, but its dysregulation underlies prevalent metabolic disorders such as obesity, type 2 diabetes, and nonalcoholic fatty liver disease. The Gene Ontology term GO:0010888, negative regulation of lipid storage, encompasses any process that decreases the rate, frequency, or extent of lipid storage. Understanding the molecular mechanisms that restrain lipid accumulation is therefore of paramount importance for both basic cell biology and therapeutic development. Research has identified multiple layers of regulation, including proteasomal degradation of lipolytic enzymes, autophagic turnover of lipid droplets, and hormonal signaling that modulates lipase activity. These findings have been accelerated by CRISPR gene editing, which enables precise perturbation of candidate genes in cell models and animal systems. This article synthesizes current knowledge on GO:0010888, highlighting key genes, regulatory pathways, disease connections, and state-of-the-art research methodologies.
negative regulation of lipid storage At A Glance
| GO ID | GO:0010888 |
|---|---|
| GO term | negative regulation of lipid storage |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the rate, frequency, or extent of lipid storage |
| Related processes | Lipolysis, lipophagy, lipid droplet turnover, proteasomal degradation of lipases |
| Key regulators | ATGL (PNPLA2), ATG14, ZDHHC1, STAT2, SLC27A3, PINK1 |
| Disease relevance | Type 2 diabetes, lipodystrophy, steatotic liver disease, cancer |
What Is GO:0010888?
GO:0010888, negative regulation of lipid storage, is defined as any biological process that decreases the rate, frequency, or extent of lipid storage. Lipid storage itself refers to the accumulation and maintenance of lipids, which are compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents, within cells or tissues. Lipid reserves can be accumulated during early developmental stages for later mobilization and utilization. Thus, negative regulation of lipid storage encompasses molecular events that inhibit the formation, growth, or persistence of lipid droplets, thereby reducing the net amount of stored lipids.
Why Is negative regulation of lipid storage Important in Cell Biology?
Negative regulation of lipid storage is central to metabolic health because excessive lipid accumulation in non-adipose tissues leads to lipotoxicity, insulin resistance, and organ dysfunction. Conversely, insufficient lipid storage can cause lipodystrophy and metabolic complications. Understanding how cells restrict lipid storage provides mechanistic insights into diseases such as type 2 diabetes, fatty liver disease, and certain cancers, where lipid metabolism is reprogrammed. Moreover, key enzymes and pathways involved in this process are attractive targets for therapeutic intervention, and CRISPR-based models are indispensable for validating causal relationships and developing targeted therapies.
• Maintains energy homeostasis by preventing excessive lipid accumulation in adipocytes and other tissues.
• Protects against lipotoxicity in non-adipose tissues such as liver, muscle, and pancreatic beta cells.
• Dysregulation is linked to type 2 diabetes, where impaired beta-cell function and lipid droplet accumulation contribute to disease progression.
• Plays a role in cancer biology, as lipid storage regulation affects tumor growth and drug resistance, e.g., in clear cell renal cell carcinoma.
• Influences systemic metabolic health through adipocyte death and macrophage infiltration in steatotic liver disease.
• Provides targets for therapeutic intervention in metabolic disorders and cancers.
• CRISPR screening and gene editing enable functional dissection of regulatory networks controlling lipid storage.
• Advances in imaging and proteomics allow real-time monitoring of lipid droplet dynamics and protein interactions.
What Happens During negative regulation of lipid storage?
Activation of Lipolysis
In simple terms: Cells break down stored fat into free fatty acids and glycerol for energy or other uses.
Lipolysis is the primary catabolic process that reduces lipid storage. It is mediated by lipases such as adipose triglyceride lipase (ATGL, gene PNPLA2), hormone-sensitive lipase (HSL), and monoglyceride lipase (MGL). ATGL catalyzes the first step of triglyceride hydrolysis, and its activity is tightly regulated by post-translational modifications and protein-protein interactions. Negative regulation of lipid storage often involves upregulation or activation of these lipases, leading to decreased lipid droplet size and number.
Proteasomal Degradation of Lipases
In simple terms: Cells can destroy the enzymes that break down fat, which would normally increase fat storage; but when these enzymes are degraded, lipid storage is promoted, not negatively regulated. However, the reverse—stabilizing lipases—reduces storage.
The N-end rule pathway mediates proteasomal degradation of ATGL, and inhibition of this degradation stabilizes ATGL, thereby enhancing lipolysis and negatively regulating lipid storage. This mechanism highlights how controlled protein turnover directly impacts lipid storage capacity. Modulating the N-end rule pathway could therefore be a strategy to reduce lipid accumulation.
Lipophagy and Lipid Droplet Turnover
In simple terms: Cells can eat their own fat droplets through a process similar to autophagy, reducing stored fat.
ATG14, an autophagy-related protein, targets lipid droplets and acts as an autophagic receptor for syntaxin18-regulated lipid droplet turnover. This process, termed lipophagy, delivers lipid droplets to lysosomes for degradation, thereby decreasing lipid storage. Activation of ATG14 or related autophagy components promotes lipid droplet clearance and negatively regulates lipid storage.
Hormonal and Signaling Regulation
In simple terms: Hormones like insulin and adrenaline control whether fat is stored or burned.
Insulin promotes lipid storage by activating lipogenesis and inhibiting lipolysis, while catecholamines and other hormones stimulate lipolysis via cAMP-PKA signaling. Negative regulation of lipid storage can be achieved by factors that mimic or enhance lipolytic signaling or that inhibit lipogenic pathways. For example, STAT2/SLC27A3/PINK1-mediated mitophagy remodels lipid metabolism and contributes to drug resistance in clear cell renal cell carcinoma, indicating complex signaling crosstalk.
Regulation of Lipid Droplet-Associated Proteins
In simple terms: Proteins on the surface of fat droplets can either protect them or mark them for breakdown.
Perilipins and other lipid droplet-associated proteins play crucial roles in lipid storage. Negative regulation can occur through changes in the composition or post-translational modification of these proteins, affecting lipid droplet stability and interaction with lipases or autophagy machinery. For instance, ZDHHC1 downregulates LIPG and inhibits colorectal cancer growth via IGF2BP1 palmitoylation, linking lipid metabolism to tumor suppression.
Key Genes Involved in GO:0010888 negative regulation of lipid storage
The following genes and proteins are central to the negative regulation of lipid storage, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PNPLA2 (ATGL) | Catalyzes first step of triglyceride hydrolysis; promotes lipolysis | Key target for enhancing lipid breakdown; regulated by N-end rule degradation |
| ATG14 | Autophagic receptor for lipid droplets; mediates lipophagy | Overexpression reduces lipid storage; potential therapeutic target |
| ZDHHC1 | Palmitoyltransferase that downregulates LIPG; inhibits cancer growth | Links lipid metabolism to tumor suppression; potential biomarker |
| LIPG | Endothelial lipase; involved in lipoprotein metabolism | Downregulated by ZDHHC1; affects lipid storage and cancer progression |
| IGF2BP1 | RNA-binding protein; mediates palmitoylation effects | Modulates LIPG expression; potential target in colorectal cancer |
| STAT2 | Transcription factor; mediates mitophagy remodeling | Involved in pazopanib resistance via lipid metabolism |
| SLC27A3 | Fatty acid transport protein; affects lipid metabolism | Part of STAT2/SLC27A3/PINK1 axis in clear cell renal cell carcinoma |
| PINK1 | Mitophagy regulator; affects lipid metabolism | Contributes to drug resistance in ccRCC |
| S100A8 | Macrophage marker; promotes inflammation | Adipocyte death promotes hepatic infiltration in steatotic liver disease |
| HSL (LIPE) | Hormone-sensitive lipase; hydrolyzes diacylglycerols | Key enzyme in lipolysis; regulated by phosphorylation |
| MGL (MGLL) | Monoglyceride lipase; completes triglyceride hydrolysis | Essential for full lipolysis; target for metabolic studies |
| Perilipin 1 (PLIN1) | Lipid droplet coat protein; regulates lipase access | Modulates lipid storage; phosphorylation triggers lipolysis |
| CGI-58 (ABHD5) | Co-activator of ATGL | Stimulates ATGL activity; mutations cause Chanarin-Dorfman syndrome |
| G0S2 | Inhibitor of ATGL | Negatively regulates lipolysis; promotes lipid storage |
| FSP27 (CIDEC) | Lipid droplet fusion protein | Enhances lipid storage; knockdown reduces lipid droplet size |
| mTOR | Kinase; regulates lipogenesis and lipolysis | Integrates nutrient signals to control lipid storage |
| AMPK | Energy sensor; inhibits lipogenesis, promotes lipolysis | Phosphorylates ACC and other targets; negative regulator of lipid storage |
How Is negative regulation of lipid storage Regulated?
Negative regulation of lipid storage is controlled by a complex network of signaling pathways. The cAMP-PKA pathway is a major activator of lipolysis: upon hormonal stimulation (e.g., catecholamines), PKA phosphorylates perilipin 1 and HSL, promoting lipase access to lipid droplets. Conversely, insulin signaling via AKT inhibits lipolysis and stimulates lipogenesis, thereby reducing negative regulation of lipid storage. AMPK, an energy sensor, phosphorylates acetyl-CoA carboxylase (ACC) and other targets to inhibit lipogenesis and enhance fatty acid oxidation, contributing to decreased lipid storage. The N-end rule pathway regulates ATGL stability, with inhibition of this pathway leading to increased ATGL levels and enhanced lipolysis. Autophagic pathways, particularly those involving ATG14, are also regulated by nutrient status and stress signals, linking lipid droplet turnover to cellular quality control. Additionally, mitophagy-related proteins such as PINK1 modulate lipid metabolism in cancer cells, affecting drug resistance. These regulatory layers ensure that lipid storage is dynamically adjusted to meet cellular energy demands and systemic metabolic cues.
negative regulation of lipid storage and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PNPLA2 (ATGL) | Type 2 diabetes, lipodystrophy | Knockout and knock-in mouse models; adipocyte-specific overexpression |
| ATG14 | Metabolic disorders, cancer | Knockout cell lines; overexpression in hepatocytes |
| ZDHHC1 | Colorectal cancer | Knockout and overexpression in cancer cell lines; xenograft models |
| STAT2/SLC27A3/PINK1 | Clear cell renal cell carcinoma, drug resistance | Knockout and rescue experiments in ccRCC cell lines |
| S100A8 | Steatotic liver disease | Macrophage-specific knockout mice; adipocyte co-culture |
Type 2 Diabetes and Beta-Cell Dysfunction
In type 2 diabetes, chronic lipid oversupply leads to lipid droplet accumulation in pancreatic beta cells, impairing insulin secretion and promoting beta-cell demise. Negative regulation of lipid storage is critical for maintaining beta-cell function; enhancing lipolysis or lipophagy could protect against lipotoxicity. ATGL and autophagy pathways are potential targets for therapeutic intervention.
Lipodystrophy and Adipocyte Dysfunction
Surplus fatty acid synthesis in adipocytes increases oxidative stress and induces lipodystrophy, a condition characterized by loss of adipose tissue and ectopic lipid accumulation. Negative regulation of lipid storage is impaired in this context, highlighting the need for balanced lipid handling. Adipocyte death promotes hepatic infiltration of S100A8+ macrophages and steatotic liver disease progression in mice, linking adipocyte lipid storage regulation to liver pathology.
Cancer and Drug Resistance
Lipid metabolism reprogramming is a hallmark of cancer. In clear cell renal cell carcinoma, STAT2/SLC27A3/PINK1-mediated mitophagy remodels lipid metabolism and contributes to pazopanib resistance. ZDHHC1 downregulates LIPG and inhibits colorectal cancer growth, demonstrating that negative regulation of lipid storage can suppress tumorigenesis. Targeting these pathways may overcome drug resistance.
Steatotic Liver Disease
Adipocyte death triggers hepatic infiltration of S100A8+ macrophages, promoting steatotic liver disease progression in mice. This underscores the systemic impact of dysregulated lipid storage in adipose tissue on liver health. Enhancing negative regulation of lipid storage in adipocytes could mitigate liver inflammation and steatosis.
From negative regulation of lipid storage-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ATGL increase lipid storage? | ATGL knockout cell lines (e.g., HepG2, 3T3-L1) and mice |
| Does ATG14 overexpression reduce lipid droplets? | ATG14 overexpression in hepatocytes or adipocytes; imaging of lipid droplets |
| Does ZDHHC1 palmitoylation affect LIPG and tumor growth? | ZDHHC1 knockout and point mutant (palmitoylation-deficient) in colorectal cancer cells |
| Does STAT2/SLC27A3/PINK1 axis mediate pazopanib resistance? | Knockout of each gene in ccRCC cells; drug sensitivity assays |
| Does S100A8+ macrophage infiltration depend on adipocyte death? | Adipocyte-specific knockout of pro-death genes; macrophage migration assays |
| Can CRISPR activation of lipolysis genes reduce steatosis? | CRISPRa overexpression of ATGL or ATG14 in liver organoids |
How to Study the negative regulation of lipid storage Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Gene function loss and lipid droplet accumulation | Identify negative regulators of lipid storage |
| CRISPR activation (CRISPRa) | Gene overexpression and lipid storage reduction | Validate sufficiency of candidate genes |
| BODIPY staining + microscopy | Lipid droplet number, size, and localization | Visualize lipid storage changes |
| Immunoblotting | Protein expression and post-translational modifications | Assess ATGL degradation, ZDHHC1 palmitoylation |
| Lipolysis assay (glycerol release) | Rate of triglyceride hydrolysis | Measure ATGL/HSL activity |
| RNA-seq | Transcriptional changes in lipid metabolism genes | Identify pathways altered by perturbations |
| Proteomics (LC-MS/MS) | Protein interactions and modifications | Discover lipid droplet-associated proteins |
| Metabolic flux analysis | Fatty acid oxidation and lipogenesis rates | Quantify metabolic shifts |
CRISPR Screening for Lipid Storage Regulators
Genome-wide CRISPR knockout or activation screens coupled with lipid droplet staining (e.g., BODIPY) can identify genes that negatively regulate lipid storage. Such screens have revealed novel regulators and validated known pathways. Hits can be further validated by targeted knockout and lipid quantification.
Imaging Lipid Droplets and Autophagy
Fluorescence microscopy with lipid droplet dyes (BODIPY, Oil Red O) and autophagy markers (LC3, ATG14) allows real-time visualization of lipid storage and turnover. Live-cell imaging can track lipid droplet dynamics and lipophagy. Co-localization studies confirm interactions between ATG14 and lipid droplets.
Proteomics and Post-Translational Modification Analysis
Mass spectrometry-based proteomics can identify proteins associated with lipid droplets and detect post-translational modifications such as palmitoylation (e.g., ZDHHC1-mediated) and ubiquitination (e.g., ATGL degradation). These approaches reveal regulatory mechanisms and potential drug targets.
Metabolic Flux Analysis
Seahorse assays, isotope tracing, and lipolysis measurements (free glycerol/fatty acid release) quantify lipid storage and breakdown rates. These methods are used to assess the impact of genetic perturbations on lipid metabolism.
How CRISPR Can Be Used to Study GO:0010888 negative regulation of lipid storage
Knockout
CRISPR knockout of genes such as PNPLA2 (ATGL) or ATG14 leads to increased lipid storage, confirming their role in negative regulation. Knockout models are essential for loss-of-function studies and for validating screening hits. For example, ATGL knockout in adipocytes results in massive lipid accumulation.
Point Mutation
Point mutations can be introduced to disrupt specific domains or post-translational modification sites. For instance, mutating the palmitoylation site of ZDHHC1 or the ubiquitination site of ATGL can reveal regulatory mechanisms. Such models are valuable for dissecting precise molecular interactions.
Knock-in
Knock-in of tagged versions (e.g., GFP, HA) of ATG14 or ATGL allows real-time tracking and interaction studies. Knock-in of disease-associated mutations can model human conditions and test therapeutic strategies. This approach is particularly useful for studying lipid droplet dynamics in live cells.
Overexpression
CRISPR activation or cDNA overexpression of genes like ATG14 or ATGL enhances lipid breakdown and reduces lipid storage. Overexpression models are used to test sufficiency and to identify downstream effects. They are also valuable for drug screening to find enhancers of negative regulation.
How EDITGENE Supports negative regulation of lipid storage Research
Researchers studying negative regulation of lipid storage-related genes often need to determine whether a candidate gene is causally involved in lipid droplet dynamics, metabolic disease, or cancer. EDITGENE provides comprehensive CRISPR gene editing services to accelerate this discovery process, from knockout to precise point mutations and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of lipid storage research.
Frequently Asked Questions About negative regulation of lipid storage
What is negative regulation of lipid storage?
Negative regulation of lipid storage (GO:0010888) refers to any biological process that decreases the rate, frequency, or extent of lipid storage, thereby reducing the accumulation of lipids in cells or tissues.
What genes are involved in negative regulation of lipid storage?
Key genes include PNPLA2 (ATGL), ATG14, ZDHHC1, LIPG, STAT2, SLC27A3, PINK1, and S100A8, among others.
How does ATGL regulate lipid storage?
ATGL (PNPLA2) catalyzes the first step of triglyceride hydrolysis; its activity promotes lipolysis and reduces lipid storage. Its degradation via the N-end rule pathway decreases lipolysis and increases storage.
What is the role of autophagy in lipid storage?
Autophagy, particularly lipophagy mediated by ATG14, targets lipid droplets for lysosomal degradation, thereby negatively regulating lipid storage.
How is negative regulation of lipid storage linked to diabetes?
Impaired negative regulation leads to lipid accumulation in pancreatic beta cells, contributing to beta-cell dysfunction and type 2 diabetes.
Can CRISPR be used to study lipid storage regulation?
Yes, CRISPR knockout, activation, and knock-in models enable precise manipulation of genes like ATGL and ATG14 to study their effects on lipid storage.
What diseases are associated with dysregulated lipid storage?
Diseases include type 2 diabetes, lipodystrophy, steatotic liver disease, and certain cancers such as colorectal and renal cell carcinoma.
What methods are used to measure lipid storage?
Common methods include BODIPY staining with microscopy, lipolysis assays measuring glycerol release, and metabolic flux analysis.
How does ZDHHC1 affect lipid storage?
ZDHHC1 downregulates LIPG via IGF2BP1 palmitoylation, inhibiting colorectal cancer growth and affecting lipid metabolism.
What is the role of S100A8 in lipid storage-related disease?
S100A8+ macrophages infiltrate the liver following adipocyte death, promoting steatotic liver disease progression in mice.
Conclusion
Negative regulation of lipid storage (GO:0010888) is a critical biological process that prevents excessive lipid accumulation and protects against metabolic diseases. Key mechanisms include activation of lipolysis, proteasomal degradation of lipases, autophagic lipid droplet turnover, and hormonal signaling. Genes such as ATGL, ATG14, and ZDHHC1 play central roles, and their dysregulation contributes to type 2 diabetes, lipodystrophy, steatotic liver disease, and cancer. CRISPR-based models are indispensable for dissecting these pathways and identifying therapeutic targets. EDITGENE offers comprehensive gene editing services to support research in this field, from knockout to overexpression and screening.
References
- 1. Yang A et al.. 2020. Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics.. Biochem J 477(5):985-1008 PMID: 32168372
- 2. Zhang Q et al.. 2024. ZDHHC1 downregulates LIPG and inhibits colorectal cancer growth via IGF2BP1 Palmitoylation.. Cancer Gene Ther 31(9):1427-1437 PMID: 39069526
- 3. Yuan Z et al.. 2024. ATG14 targets lipid droplets and acts as an autophagic receptor for syntaxin18-regulated lipid droplet turnover.. Nat Commun 15(1):631 PMID: 38245527
- 4. Lu D et al.. 2024. STAT2/SLC27A3/PINK1-Mediated Mitophagy Remodeling Lipid Metabolism Contributes to Pazopanib Resistance in Clear Cell Renal Cell Carcinoma.. Research (Wash D C) 7:0539 PMID: 39600540
- 5. Weng L et al.. 2024. Surplus fatty acid synthesis increases oxidative stress in adipocytes and lnduces lipodystrophy.. Nat Commun 15(1):133 PMID: 38168040
- 6. Xu J et al.. 2023. N-end Rule-Mediated Proteasomal Degradation of ATGL Promotes Lipid Storage.. Diabetes 72(2):210-222 PMID: 36346641
- 7. Tong X et al.. 2022. Lipid Droplets' Role in the Regulation of β-Cell Function and β-Cell Demise in Type 2 Diabetes.. Endocrinology 163(3) PMID: 35086144
- 8. Guan Y et al.. 2025. Adipocyte death promotes hepatic infiltration of S100A8+ macrophages and steatotic liver disease progression in mice.. J Clin Invest 135(21) PMID: 41178716
